Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entera Bio (ENTX) Common Equity (2017 - 2025)

Entera Bio has reported Common Equity over the past 9 years, most recently at $13.1 million for Q4 2025.

  • For the quarter ending Q4 2025, Common Equity rose 62.14% year-over-year to $13.1 million, compared with a TTM value of $13.1 million through Dec 2025, up 62.14%, and an annual FY2025 reading of $13.1 million, up 62.14% over the prior year.
  • Common Equity came in at $13.1 million for Q4 2025, down from $15.2 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $26.3 million in Q2 2021 to a low of $6.2 million in Q3 2023.
  • Median Common Equity over the past 5 years was $13.7 million (2022), compared with a mean of $14.3 million.
  • The sharpest move saw Common Equity surged 200.47% in 2021, then plummeted 56.43% in 2023.
  • Over 5 years, Common Equity stood at $22.6 million in 2021, then plummeted by 47.91% to $11.8 million in 2022, then decreased by 11.64% to $10.4 million in 2023, then fell by 22.2% to $8.1 million in 2024, then soared by 62.14% to $13.1 million in 2025.
  • Per Business Quant, the three most recent readings for ENTX's Common Equity are $13.1 million (Q4 2025), $15.2 million (Q3 2025), and $17.3 million (Q2 2025).